PremiumThe FlyAlcon price target raised to $120 from $115 at Mizuho Alcon’s Growth Prospects Boosted by Robust Product Pipeline and Market Opportunities: Buy Rating Affirmed Alcon acquires majority interest in Aurion Biotech PremiumRatingsPositive Outlook for Alcon: Buy Rating Supported by Earnings Upgrade Cycle and Attractive Valuation Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit Alcon to acquire Lensar for $430M PremiumCompany AnnouncementsAlcon Reports Strong Financial Performance and Growth Alcon’s Strong Q4 Performance and Strategic Growth Initiatives Earn Buy Rating from Analyst Alcon’s Mixed Q4 FY24 Results Lead to Hold Rating Amid Promising Pipeline and Strategic Growth Focus 
